Jason Kirk

891 total citations
17 papers, 491 citations indexed

About

Jason Kirk is a scholar working on Molecular Biology, Pulmonary and Respiratory Medicine and Oncology. According to data from OpenAlex, Jason Kirk has authored 17 papers receiving a total of 491 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Molecular Biology, 8 papers in Pulmonary and Respiratory Medicine and 5 papers in Oncology. Recurrent topics in Jason Kirk's work include Prostate Cancer Treatment and Research (8 papers), Radiopharmaceutical Chemistry and Applications (2 papers) and Multiple Myeloma Research and Treatments (2 papers). Jason Kirk is often cited by papers focused on Prostate Cancer Treatment and Research (8 papers), Radiopharmaceutical Chemistry and Applications (2 papers) and Multiple Myeloma Research and Treatments (2 papers). Jason Kirk collaborates with scholars based in United States, Netherlands and United Kingdom. Jason Kirk's co-authors include Dean G. Tang, Dingxiao Zhang, Yibing Ji, Xinyun Li, Shuhong Zhao, Qiang Hu, Jianmin Wang, John E. Davis, Hsueh‐Ping Chao and Spencer R. Rosario and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and PLoS ONE.

In The Last Decade

Jason Kirk

16 papers receiving 487 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Jason Kirk United States	12	293	136	133	123	44	17	491
Qing-Rong Chen United States	9	289 1.0×	93 0.7×	140 1.1×	105 0.9×	29 0.7×	9	484
Mariangela Balistreri Italy	10	270 0.9×	219 1.6×	89 0.7×	124 1.0×	23 0.5×	15	487
Hsi Chin Wu Taiwan	11	216 0.7×	125 0.9×	203 1.5×	130 1.1×	14 0.3×	22	502
Véronique Barrès Canada	10	212 0.7×	82 0.6×	59 0.4×	99 0.8×	24 0.5×	19	373
Jue‐Yu Zhou China	15	426 1.5×	278 2.0×	54 0.4×	110 0.9×	20 0.5×	42	591
Daniela Morales-Espinosa Spain	12	206 0.7×	155 1.1×	190 1.4×	276 2.2×	39 0.9×	25	534
Takehisa Suzuki Japan	12	218 0.7×	87 0.6×	146 1.1×	132 1.1×	11 0.3×	28	433
Ji-Hai Yu China	12	276 0.9×	143 1.1×	46 0.3×	140 1.1×	20 0.5×	19	483
Ceren Gönen Korkmaz Norway	10	226 0.8×	82 0.6×	142 1.1×	84 0.7×	10 0.2×	14	450
Jürgen Stahl Australia	10	216 0.7×	75 0.6×	85 0.6×	87 0.7×	16 0.4×	20	364

Countries citing papers authored by Jason Kirk

Since Specialization

Citations

This map shows the geographic impact of Jason Kirk's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jason Kirk with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jason Kirk more than expected).

Fields of papers citing papers by Jason Kirk

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jason Kirk. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jason Kirk. The network helps show where Jason Kirk may publish in the future.

Co-authorship network of co-authors of Jason Kirk

This figure shows the co-authorship network connecting the top 25 collaborators of Jason Kirk. A scholar is included among the top collaborators of Jason Kirk based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jason Kirk. Jason Kirk is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

17 of 17 papers shown

Perimbeti, Stuthi, Dharmesh Gopalakrishnan, Rohit Jain, et al.. (2025). Phase Ib study of enzalutamide with venetoclax in patients with metastatic castration-resistant prostate cancer. Cancer Chemotherapy and Pharmacology. 95(1). 115–115.

Perimbeti, Stuthi, Kristopher Attwood, Jan H. Beumer, et al.. (2023). Phase Ib trial of enzalutamide (Enza) with venetoclax (Ven) in metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology. 41(6_suppl). 182–182. 4 indexed citations

Long, Mark D., Prashant K. Singh, Sajad A. Wani, et al.. (2021). Reduced NCOR2 expression accelerates androgen deprivation therapy failure in prostate cancer. Cell Reports. 37(11). 110109–110109. 20 indexed citations

Zhang, Dingxiao, Qiang Hu, Xiaozhuo Liu, et al.. (2020). Intron retention is a hallmark and spliceosome represents a therapeutic vulnerability in aggressive prostate cancer. Nature Communications. 11(1). 2089–2089. 88 indexed citations

Gopalakrishnan, Dharmesh, Jason Kirk, John W. Davis, et al.. (2020). A phase Ib trial of enzalutamide with venetoclax in metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology. 38(15_suppl). TPS5599–TPS5599. 1 indexed citations

Chao, Hsueh‐Ping, Yueping Chen, Yoko Takata, et al.. (2019). Systematic evaluation of RNA-Seq preparation protocol performance. BMC Genomics. 20(1). 571–571. 27 indexed citations

Davis, John E., Jason Kirk, Yibing Ji, & Dean G. Tang. (2019). Tumor Dormancy and Slow-Cycling Cancer Cells. Advances in experimental medicine and biology. 1164. 199–206. 41 indexed citations

Billger, Martin, et al.. (2019). A study in a rat initiation-promotion bladder tumour model demonstrated no promoter/progressor potential of dapagliflozin. Regulatory Toxicology and Pharmacology. 103. 166–173. 11 indexed citations

Zhang, Dingxiao, Shuhong Zhao, Xinyun Li, Jason Kirk, & Dean G. Tang. (2018). Prostate Luminal Progenitor Cells in Development and Cancer. Trends in cancer. 4(11). 769–783. 62 indexed citations

10.

Long, Mark D., Prashant K. Singh, James R. Russell, et al.. (2018). The miR-96 and RARγ signaling axis governs androgen signaling and prostate cancer progression. Oncogene. 38(3). 421–444. 38 indexed citations

11.

Lasorsa, Elena, et al.. (2016). EZH2 inhibition re-sensitizes multidrug resistant B-cell lymphomas to etoposide mediated apoptosis. Oncoscience. 3(1). 21–30. 9 indexed citations

12.

Lasorsa, Elena, et al.. (2015). Mitochondrial protection impairs BET bromodomain inhibitor-mediated cell death and provides rationale for combination therapeutic strategies. Cell Death and Disease. 6(12). e2014–e2014. 18 indexed citations

13.

Kirk, Jason, Ellen Karasik, Bryan M. Gillard, et al.. (2014). Early Growth Inhibition Is Followed by Increased Metastatic Disease with Vitamin D (Calcitriol) Treatment in the TRAMP Model of Prostate Cancer. PLoS ONE. 9(2). e89555–e89555. 26 indexed citations

14.

Cove-Smith, Laura, Neil Woodhouse, Adam Hargreaves, et al.. (2014). An Integrated Characterization of Serological, Pathological, and Functional Events in Doxorubicin-Induced Cardiotoxicity. Toxicological Sciences. 140(1). 3–15. 50 indexed citations

15.

Kirk, Jason, Elena Lasorsa, Sheng‐Yu Ku, et al.. (2014). Top2a identifies and provides epigenetic rationale for novel combination therapeutic strategies for aggressive prostate cancer. Oncotarget. 6(5). 3136–3146. 48 indexed citations

16.

Nadiminty, Nagalakshmi, Wei Lou, Soo Ok Lee, et al.. (2006). Prostate-Specific Antigen Modulates Genes Involved in Bone Remodeling and Induces Osteoblast Differentiation of Human Osteosarcoma Cell Line SaOS-2. Clinical Cancer Research. 12(5). 1420–1430. 45 indexed citations

17.

Wong, Michael K.K., Ruth A. Modzelewski, Gregory Weller, et al.. (2004). Ultrasound contrast visualization of tumor vasculature in vivo by targeted microbubbles. Journal of Clinical Oncology. 22(14_suppl). 3198–3198. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact